- Home
- SQNS vs SLS Comparison
SQNS vs SLS Comparison
Compare SQNS & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SQNS
- SLS
- Stock Information
- Founded
- SQNS 2003
- SLS 2012
- Country
- SQNS France
- SLS United States
- Employees
- SQNS N/A
- SLS N/A
- Industry
- SQNS Semiconductors
- SLS Biotechnology: Pharmaceutical Preparations
- Sector
- SQNS Technology
- SLS Health Care
- Exchange
- SQNS Nasdaq
- SLS Nasdaq
- Market Cap
- SQNS 85.7M
- SLS 69.6M
- IPO Year
- SQNS 2011
- SLS N/A
- Fundamental
- Price
- SQNS $3.14
- SLS $1.49
- Analyst Decision
- SQNS Strong Buy
- SLS
- Analyst Count
- SQNS 1
- SLS 0
- Target Price
- SQNS $7.50
- SLS N/A
- AVG Volume (30 Days)
- SQNS 135.2K
- SLS 5.3M
- Earning Date
- SQNS 02-11-2025
- SLS 03-27-2025
- Dividend Yield
- SQNS N/A
- SLS N/A
- EPS Growth
- SQNS N/A
- SLS N/A
- EPS
- SQNS 1.65
- SLS N/A
- Revenue
- SQNS $30,555,000.00
- SLS N/A
- Revenue This Year
- SQNS $10.14
- SLS N/A
- Revenue Next Year
- SQNS $8.54
- SLS N/A
- P/E Ratio
- SQNS $1.83
- SLS N/A
- Revenue Growth
- SQNS N/A
- SLS N/A
- 52 Week Low
- SQNS $0.85
- SLS $0.59
- 52 Week High
- SQNS $7.43
- SLS $1.84
- Technical
- Relative Strength Index (RSI)
- SQNS 48.85
- SLS 63.02
- Support Level
- SQNS $3.00
- SLS $1.24
- Resistance Level
- SQNS $3.64
- SLS $1.84
- Average True Range (ATR)
- SQNS 0.21
- SLS 0.22
- MACD
- SQNS -0.03
- SLS 0.05
- Stochastic Oscillator
- SQNS 39.76
- SLS 64.65
About SQNS Sequans Communications S.A.
Sequans Communications SA is a designer, developer, and supplier of cellular semiconductor solutions for broadband Internet of Things (IoT) markets. Its solutions incorporate baseband processor and radio frequency, transceiver integrated circuits, along with its proprietary signal processing techniques, algorithms, and software stacks. The company's solutions serve as the core wireless broadband communications platform in devices, including smartphones, USB dongles, portable routers, laptops, netbooks, tablets, and other consumer multimedia and industrial devices. Its geographical segments are Taiwan, Korea, China (including Hong Kong), the Rest of Asia, the United States and the Rest of the world.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.